Morepen Laboratories Q1 FY27: Board meet Aug 4, 2026

What the company has announced

Morepen Laboratories Limited has scheduled a meeting of its Board of Directors on August 4, 2026. The meeting is set to review and approve the company’s un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. This places the focus on the company’s Q1 FY27 performance, a quarter that also included an operational milestone on its contract manufacturing side. The update comes after the company reported mixed trends in Q4 FY26, with revenue rising year-on-year but profit declining.

Board meeting agenda and Q1 FY27 timeline

The company has stated that the August 4, 2026 board meeting will consider and approve Q1 FY27 standalone and consolidated results. Q1 FY27 refers to the quarter ended June 30, 2026. The last reported earnings date mentioned is May 26, 2026, for Q4 FY25-26. For investors, the board meeting date is the next formal checkpoint for updated numbers and management commentary through the quarterly filing.

CDMO update: first commercial dispatch in Q1 FY27

During Q1 FY27, Morepen completed its first commercial dispatch valued at approximately ₹50 crore. This dispatch was made under a multi-year global CDMO mandate valued at ₹825 crore. The company has positioned this as a step in executing that larger mandate. While the dispatch value is only a fraction of the total mandate, it provides a concrete datapoint from the quarter that will be discussed alongside financial results.

Q1 FY27 expectations cited in the article (Uniresearch)

The article also includes a Q1 FY27 results preview attributed to Uniresearch. As per that estimate, Morepen Laboratories’ Q1 FY27 revenue is projected at ₹397 crore, which implies a year-on-year change of -6.6%. The same estimate projects profit after tax (PAT) at ₹6 crore, implying -50.0% year-on-year.

The preview notes that Q1 FY26 is used as the base, with revenue of ₹425 crore and PAT of ₹11 crore. The estimate is described as directional rather than a guaranteed outcome. Investors typically treat such previews as a reference point and wait for the company’s filed results for confirmed numbers.

Recap: consolidated performance in Q4 FY26

For the quarter ended March 31, 2026 (Q4 FY26), the company’s consolidated net profit was reported at ₹15.70 crore. This represented a year-on-year decline of 22.54% from ₹20.31 crore in Q4 FY25. Consolidated total revenue for Q4 FY26 was ₹484.71 crore, up 4.04% year-on-year from ₹465.85 crore.

The article further breaks out consolidated revenue from operations for Q4 FY26 at ₹484.72 crore, showing 0.11% growth quarter-on-quarter versus ₹484.16 crore in Q3 FY26 and 4.05% growth year-on-year versus ₹465.85 crore in Q4 FY25. Consolidated total income for Q4 FY26 stood at ₹493.18 crore, up 1.07% quarter-on-quarter from ₹487.97 crore. Consolidated profit before tax (PBT) for Q4 FY26 was ₹23.29 crore, down 34.25% quarter-on-quarter from ₹35.42 crore and down 9.44% year-on-year from ₹25.71 crore. Net profit after minority interest for Q4 FY26 was stated at ₹15.74 crore.

Recap: standalone highlights for Q4 FY26

On a standalone basis, revenue from operations in Q4 FY26 was ₹462.81 crore. This was up 1.15% quarter-on-quarter from ₹457.57 crore and up 21.17% year-on-year from ₹381.94 crore. Total standalone income for Q4 FY26 was ₹471.63 crore, compared with ₹461.50 crore in Q3 FY26 and ₹385.08 crore in Q4 FY25.

Standalone profit before tax for Q4 FY26 was ₹27.63 crore, down 12.08% quarter-on-quarter from ₹31.42 crore, and up 59.65% year-on-year from ₹17.30 crore. Standalone net profit in Q4 FY26 was ₹20.12 crore, down 14.35% from ₹23.50 crore in Q3 FY26 and up 68.94% from ₹11.91 crore in Q4 FY25. Standalone EBITDA for March 2026 quarter was ₹32.13 crore, down 3.51% from ₹33.30 crore in March 2025. Standalone EPS for March 2026 quarter was ₹0.37, compared with ₹0.20 in March 2025.

Full-year FY26 snapshot mentioned in the article

For FY26, consolidated revenue from operations was reported at ₹1,805.69 crore, a marginal decline of 0.32% versus ₹1,811.58 crore in FY25. Annual EPS for FY26 was ₹1.73 compared to ₹2.20 in FY25.

For FY26 standalone, revenue from operations was ₹1,681.20 crore, up 8.15% from ₹1,554.54 crore in FY25. Annual standalone net profit for FY26 was ₹66.06 crore, compared to ₹101.58 crore in FY25. These annual figures provide context for how the company exited FY26 going into the Q1 FY27 reporting cycle.

Immediate context from Q3 FY26

The article also lists Q3 FY26 numbers. Revenue for Q3 FY26 was ₹484.16 crore versus ₹452.78 crore in Q3 FY25, a change of 7%. PBT for Q3 FY26 was ₹35.42 crore versus ₹35.21 crore in Q3 FY25, a change of 1%. PAT for Q3 FY26 was ₹27.50 crore versus ₹26.69 crore in Q3 FY25, a change of 3%. EPS for Q3 FY26 was ₹0.50.

Key facts at a glance

Why the August 4 result update matters

The Q1 FY27 filing will be the first confirmed view of how the year has started, including how the CDMO dispatch is reflected in reported numbers. It will also help investors compare trends against Q4 FY26, when consolidated revenue rose but profit declined year-on-year. Since both standalone and consolidated results are on the agenda, readers can track any divergence between the two sets of numbers.

What to track next

The next concrete event disclosed is the board meeting on August 4, 2026. After the meeting, the company is expected to publish the approved un-audited results for the quarter ended June 30, 2026. Until then, the key publicly stated datapoints remain the board meeting schedule, the ₹50 crore CDMO dispatch during Q1 FY27, and the last reported quarterly and annual financial figures cited above.